Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery

Citations of this article
Mendeley users who have this article in their library.


Objective: To investigate whether there is a difference in the risk of progressing to BPH-related prostatic surgery between patients using alpha-blockers and patients using the 5-alpha-reductase inhibitors (5-ARIs). Methods: A population-based cohort study was conducted, using data from the PHARMO Record Linkage System. We identified 5671 patients (≥50 years old, no history of using both alpha-blockers and 5-ARIs, more than one year of database history prior to the first date of BPH drug-dispensing), who filled at least one prescription for either alpha-blockers (alfuzosin, tamsulosin, terazosin) or 5-ARIs (finasteride). The incidence of BPH-related surgery was compared between patients treated with alpha-blockers and patients treated with 5-ARIs. Results: The cumulative incidence of BPH-related prostatic surgery was 15.2% and mainly involved transurethral resection of the prostate (TURP) (13.4%). Patients using alpha-blockers had a significantly increased risk of BPH-related prostatic surgery compared to patients using 5-ARIs, which remained after adjusting for age, calendar time, type of prescriber and chronic disease score (adjusted HR: 1.52, 95% CI: 1.24-1.88). The difference between alpha-blockers and 5-ARIs was sustained after stratification of time period (< 1995, ≥ 1995) and exclusion of patients with prostatic surgery within one month of treatment initiation. Conclusions: It is concluded that alpha-blocker treated patients had a higher risk of BPH-related surgery compared to 5-ARI treated patients. Additional research on the long-term outcomes and risk factors for the natural progression of BPH is necessary to identify the optimal medical treatment for BPH patients according to their baseline characteristics. © 2003 Elsevier Science B.V. All rights reserved.




Souverein, P. C., Erkens, J. A., De la Rosette, J. J. M. C. H., Leufkens, H. G. M., & Herings, R. M. C. (2003). Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. European Urology, 43(5), 528–534. https://doi.org/10.1016/S0302-2838(03)00089-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free